Agios Pharmaceuticals Stock Forecast, Price & News

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGIO stock has decreased by 13.1% and is now trading at $35.50.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agios Pharmaceuticals.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.31) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.05. The biopharmaceutical company had revenue of $37.30 million for the quarter, compared to analysts' expectations of $37.17 million. Agios Pharmaceuticals had a negative return on equity of 59.71% and a negative net margin of 182.49%. The company's revenue was up 42.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.87) EPS.
View Agios Pharmaceuticals' earnings history.

14 analysts have issued twelve-month price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $82.00. On average, they expect Agios Pharmaceuticals' share price to reach $68.50 in the next year. This suggests a possible upside of 93.0% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals.

Agios Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 6,930,000 shares, an increase of 14.7% from the September 15th total of 6,040,000 shares. Based on an average daily volume of 596,200 shares, the days-to-cover ratio is currently 11.6 days.
View Agios Pharmaceuticals' Short Interest.

Some companies that are related to Agios Pharmaceuticals include CureVac B.V. (CVAC), Galapagos (GLPG), Mirati Therapeutics (MRTX), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Bausch Health Companies (BHC), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR) and Emergent Biosolutions (EBS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Celgene (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.55%), Peregrine Capital Management LLC (0.24%), Arthur M. Cohen & Associates LLC (0.00%), Nisa Investment Advisors LLC (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals.

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Arthur M. Cohen & Associates LLC, Pacer Advisors Inc., and Nisa Investment Advisors LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $35.50.

Agios Pharmaceuticals has a market capitalization of $2.45 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.

The official website for Agios Pharmaceuticals is www.agios.com.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]